Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast

Abstract

Periductal myxoid stroma and reduced periductal decorin expression seem to be prognostic for overall ipsilateral locoregional recurrence in DCIS, whereas HER2 expression might be a more specific biomarker for invasive recurrence.

Dichotomous histopathological assessment of ductal carcinomain situof the breast results in substantial interobserver concordance

“…Likewise, myxoid changes in the periductal stroma cannot be overlooked. We previously reported an association between myxoid stromal changes and recurrence rates in DCIS patients . Here, we have determined a robust cut‐off of 33% of ducts surrounded by myxoid changes, and we now aim to further explore the relationship between dichotomised periductal stromal changes and outcome in an independent cohort of DCIS patients.…”

“…The presence and degree of a chronic inflammatory infiltrate in the periductal stroma were recorded semiquantitatively as previously described . Four categories were discerned.…”

Identifying progression predictors of breast ductal carcinoma in situ

“…Based on radiological findings, high-density breast stroma has been proposed to be one of the strongest risk factors for invasive breast cancer, second only to deleterious germ line BRCA mutations 51–53. Van Bockstal et al 54 demonstrated that the presence of a predominantly myxoid periductal stroma was the only histopathological feature associated with overall recurrence risk and risk of invasive recurrence, but not with in situ recurrence. Moreover, the same group showed that myxoid stroma-associated DCIS presented significantly more often with reduced expression of periductal decorin, a protein involved in normal collagen fibrillogenesis in breast stroma 54 55.…”

“…Van Bockstal et al 54 demonstrated that the presence of a predominantly myxoid periductal stroma was the only histopathological feature associated with overall recurrence risk and risk of invasive recurrence, but not with in situ recurrence. Moreover, the same group showed that myxoid stroma-associated DCIS presented significantly more often with reduced expression of periductal decorin, a protein involved in normal collagen fibrillogenesis in breast stroma 54 55. Remodelling of the stromal ECM appears to be a prerequisite for the progression of DCIS to invasive disease, resulting in the loss of the protective functions normally offered by the cellular and acellular components of the stroma.…”

Tumor-environment biomimetics delay peritoneal metastasis formation by deceiving and redirecting disseminated cancer cells

“…The incapacity of MP[fib] to capture cancer cells suggest that fibroblast secrete anti-adhesive proteins that are captured at the surface of the MP. One such anti-adhesive matrix protein is decorin, a small leucinerich proteoglycan, massively synthesized and deposited by fibroblasts in phenotypically normal tissue [40]. Real-time monitoring of colon cancer cell adhesion to a decorin coated substrate revealed significant inhibition of adhesion compared to type I collagen stimulated adhesion [41].…”